Venous catheters play critical roles in the administration of chemotherapy, antibiotics, blood, blood products and total parenteral nutrition essential for the successful treatment of many chronic afflictions. Recent advances in catheter technology have enabled the explosive growth in oncology (vascular access ports), nephrology (hemodialysis catheters) and inpatient interventions (peripherally inserted catheters). Unfortunately, the catheter surface interaction with the blood stream has a very high potential of initiating surface thrombi that lead to serious and often life-threatening complications. To counter this risk, patients are given systemic anticoagulation drugs, which, while reducing the probability of surface clotting, introduce a second set of serious medical complications that significantly increase patient morbidity and mortality. Current treatments to prevent catheter-related thrombosis rely primarily on IV/oral anticoagulation. However, the tradeoff between long-term IV/oral anticoagulation and internal bleeding severely limits the performance of these powerful devices. Many approaches have been studied to reduce the formation of surface clots associated with the use of venous catheters, but none have met with more than minimal success. However, we have recently discovered an approach to modifying one of the most commonly used catheter biomaterials in such a manner as to drastically reduce the formation of surface clots during the long periods that such catheters must remain within the body. This modification appears to have not only the potential to be medically effective, but also to allow the fabrication of improved venous catheters with minimal or no increase in cost. In Phase I of this project, we shall compound the new plastic and conduct in-vitro tests to demonstrate that the compound (a) can be readily made, (b) that its mechanical properties are similar to those biomaterials now most commonly used for making catheters, and (c) that it has dramatically reduced tendencies to instigate the formation of surface clots in appropriate baths of platelet rich media. In Phase II, the formulation of the optimal composition of the biomaterial will be completed and actual venous catheters will be made and used for extensive in-vitro tests as well as for testing in animals. By the completion of the project, the groundwork should have been set for final engineering and rapid commercialization of anti-thrombotic venous catheters which should lead directly to substantially improved patient outcome. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
2R44RR022921-02
Application #
7481730
Study Section
Special Emphasis Panel (ZRG1-SBMI-T (10))
Program Officer
Swain, Amy L
Project Start
2006-07-01
Project End
2010-06-30
Budget Start
2008-09-23
Budget End
2009-06-30
Support Year
2
Fiscal Year
2008
Total Cost
$498,892
Indirect Cost
Name
Radiation Monitoring Devices, Inc.
Department
Type
DUNS #
073804411
City
Watertown
State
MA
Country
United States
Zip Code
02472
Miller, Stuart R; Ovechkina, Elena E; Bennett, Paul et al. (2013) Nondestructive method for quantifying thallium dopant concentrations in CsI:Tl crystals. Appl Radiat Isot 82:133-8
Kappers, L A; Bartram, R H; Hamilton, D S et al. (2010) A Tunneling Model for Afterglow Suppression in CsI:Tl,Sm Scintillation Materials. Radiat Meas 45:426-428